Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imagabalin in Generalized Anxiety Disorder
NCT00658762Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of imagabalin in generalized anxiety disorder (GAD) (4 arms), sponsored by Pfizer. Primary endpoints: Hamilton Anxiety Rating Scale at 8 weeks and Safety and Tolerability at 10 weeks. Started May 2008; status: terminated.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00658762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658762.